Abstract
Somatotroph adenomas are usually controlled with standard therapy, which can include surgery, medical treatment and radiotherapy. Some tumors have a more aggressive behavior and are refractory to standard therapy. In this review, we summarize the phenotype of these tumors and the current options for their management.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.
References
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, Endocrinology E, S.o (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1–G24
Liu X, Dai C, Feng M, Li M, Chen G, Wang R (2021) Diagnosis and treatment of refractory pituitary adenomas: a narrative review. Gland Surg 10:1499–1507
Conficoni A, Feraco P, Mazzatenta D, Zoli M, Asioli S, Zenesini C, Fabbri VP, Cellerini M, Bacci A (2020) Biomarkers of pituitary macroadenomas aggressive behaviour: a conventional MRI and DWI 3T study. Br J Radiol 93:20200321
Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM, Camacho AHS, Chimelli L, Niemeyer P, Gadelha MR, Kasuki L (2018) Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 60:415–422
Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24:238–246
Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen MC, Melmed S (2020) : Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord 21, 667–678
Wildemberg LE, Gadelha MR (2016) Pasireotide for the treatment of acromegaly. Expert Opin Pharmacother 17:579–588
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. The Lancet Diabetes & Endocrinology 2:875–884
Buchfelder M, van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger CJ, Ghigo E, Camacho-Hubner C, Pan K, Lavenberg J, Jonsson P, Hey-Hadavi JH (2018) Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol 179:419–427
Knappe UJ, Petroff D, Quinkler M, Schmid SM, Schofl C, Schopohl J, Stieg MR, Tonjes A (2020) participants of the German Acromegaly, R.: Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry. Eur J Endocrinol 182, 275–284
Singh R, Didwania P, Lehrer EJ, Sheehan D, Sheehan K, Trifiletti DM, Sheehan JP (2020) : Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes. J Neurooncol
Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L, Anile C, Colosimo C, Rindi G, Pontecorvi A, De Marinis L, Bianchi A (2019) Pasireotide and Pegvisomant Combination Treatment in Acromegaly resistant to second-line therapies: a longitudinal study. J Clin Endocrinol Metab 104:5478–5482
Luo M, Tan Y, Chen W, Hu B, Wang Z, Zhu D, Jiao H, Duan C, Zhu Y, Wang H (2021) Clinical efficacy of Temozolomide and its predictors in aggressive pituitary tumors and Pituitary Carcinomas: a systematic review and Meta-analysis. Front Neurol 12:700007
Ishida A, Shichi H, Fukuoka H, Shiramizu H, Inoshita N, Yamada S (2022) Temozolomide and Capecitabine Treatment for an aggressive Somatotroph Pituitary Tumor: a Case Report and Literature Review. Front Oncol 12:916982
Nakano-Tateno T, Lau KJ, Wang J, McMahon C, Kawakami Y, Tateno T, Araki T (2021) Multimodal Non-Surgical treatments of aggressive pituitary tumors. Front Endocrinol 12:624686
Funding
This manuscript has not received any funding.
Author information
Authors and Affiliations
Contributions
MRG and LK participated in the literature review, wrote the manuscript and reviewed all information.
Corresponding author
Ethics declarations
Competing interests
MRG has received speaker fees from Recordati Rare Diseases, Ipsen, Novo Nordisk and Crinetics and is a member of the advisory board for Crinetics, Ipsen, Recordati Rare Disease and Novo Nordisk. LK has received speaker fees from Novartis and Ipsen.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gadelha, M.R., Kasuki, L. Refractory somatotroph adenomas. Pituitary 26, 266–268 (2023). https://doi.org/10.1007/s11102-023-01324-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-023-01324-5